Philips has launched the Verisight Pro 3D echocardiography (ICE) catheter in the European market.
Able to integrate with Philips’ Epiq ultrasound system, which in turn works with its Azurion image-guided treatment platform, Philips said Verisight complements its existing European structural heart disease ecosystem.
The Dutch HealthTech giant added that Verisight's introduction in Europe is with tools like Echonavigator, which means it can now provide end-to-end solutions for clinicians such as Tricuspid and Tricuspid and mitral valve repair and replacement, atrial defect closure, and leave additional occlusions for atrial attachment.
The Verisight consists of a miniature ultrasound probe embedded in the tip of a thin, recognizable catheter, providing doctors with real-time 3D and 2D imaging directly inside the heart, whose catheters are designed to help doctors perform surgery "more obvious."
Philips said the catheter also features XPLANE and IROTATE technology, allowing doctors to simultaneously visualize two imaging planes and digitally adjust the view without physically repositioning the catheter tip, allowing for more precise imaging assessments with fewer deployment steps.
According to Philips, through femoral vein introduction, Verisight also reduces the need for general anesthesia and recovery time in the Post-Nanodymia Care Unit (PACU), which can shorten hospitalization and reduce costs.
Verisight received approval from the U.S. Food and Drug Administration (FDA) in September 2020 before the country's initial limited market launch. The first procedure occurred in July 2021 with the U.S. catheter.
Stacy Beske, a business leader in Philips’ image-guided therapy devices, said Verisight’s Europe has launched a “important milestone” that will help more patients benefit from image-guided, minimally invasive heart surgery while supporting nursing teams with a comprehensive solution “adapted to the way they work.”
"Verisight Pro reflects our ongoing commitment to delivering clinically relevant innovations that increase precision, reduce program complexity and improve nursing experience," Beske added.
Research by the European Commission (EC) shows that structural heart disease (SHD) is a significant health care burden in Europe, expected to rise from 14 million in 2020 to 20 million in 2040, mainly due to aging population.
The procedure for transcatheter aortic valve replacement (TAVR) in the treatment of SHD represents a significant growth area in the SHD treatment landscape. According to GlobalData analysis, it is estimated that the global TAVR market will be valued at approximately US$13.7 billion by 2033, up from US$6.16 billion in 2023.
According to GlobalData's U.S. Healthcare Invoice Database, major player Edwards Lifesciences, which owns more than 60% of the U.S. TAVR market, recently received FDA approval for its SAPIEN 3 TAVR platform to obtain FDA approval, which is through FDA approval for the treatment of asymptomatic inflammation patients.
However, according to GlobalData analysis, Medtronic's Evolut TAVR system can be set up to disrupt U.S. market dynamics because the data released data, which suggests that Evolut may prove to be a "excellent product."
"Philips Launching 3D Imaging Catheters in Europe" was originally created and published by GlobalData-owned brand Medical Device Network.
The information on this website is included in sincerity only for general information purposes. It is not intended to rely on the advice you should rely on, and we do not provide any representation, warranty or warranty that express or imply its accuracy or completeness. You must take or avoid any action based on the content on our website to obtain professional or professional advice.